Fig. 1From: Molecular targeting in acute myeloid leukemiaFLT3 kinase signaling pathway and sites blocked by FLT3 inhibitors. Sorafenib and quizartinib inhibit only FLT3–ITD mutations, while midostaurin, crenolanib, and gilteritinib inhibit both FLT3–ITD and FLT3 TKD mutationsBack to article page